

Clinical Policy: Teriflunomide (Aubagio)

Reference Number: CP.PHAR.262

Effective Date: 08/16

Last Review Date: 08/17

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

The intent of the criteria is to ensure that patients follow selection elements established by Centene® clinical policy for teriflunomide (Aubagio®).

Policy/Criteria

It is the policy of health plans affiliated with Centene Corporation® that Aubagio is **medically necessary** for the following indications:

I. Initial Approval Criteria

A. Multiple Sclerosis (must meet all):

1. Diagnosis of relapsing-remitting multiple sclerosis (MS);
2. Prescribed by or in consultation with a neurologist;
3. Age \geq 18 years;
4. Failure of one of the following (a or b) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced:
 - a. Avonex or Plegridy and any of the following: glatiramer (Copaxone, Glatopa), Tecfidera, Gilenya;
 - b. Any 2 of the following agents: glatiramer acetate (Copaxone, Glatopa), Tecfidera, Gilenya;
5. Member will not use other disease modifying therapies for MS concurrently;
6. At the time of request, member does not have any of the following contraindications:
 - a. Severe hepatic impairment;
 - b. Pregnancy;
 - c. Current leflunomide treatment;
7. Dose does not exceed 14 mg/day (1 tablet/day).

Approval duration: 6 months

B. Other diagnoses/indications: Refer to CP.PHAR.57 - Global Biopharm Policy

II. Continued Approval

A. Multiple Sclerosis (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Member is responding positively to therapy (e.g., improved or maintained disease control evidenced by decreased or stabilized Expanded Disability Status Scale score or reduction in relapses or magnetic resonance imaging lesions);
3. Member is not using other disease modifying therapies for MS concurrently;
4. If request is for a dose increase, new dose does not exceed 14 mg/day (1 tablet/day).

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy; or
2. Refer to CP.PHAR.57 - Global Biopharm Policy.

Background

Description/Mechanism of Action:

Teriflunomide, an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de novo pyrimidine synthesis. The exact mechanism by which teriflunomide exerts its therapeutic effect in multiple sclerosis is unknown but may involve a reduction in the number of active lymphocytes in the central nervous system.

Formulations:

Aubagio is available as 7 mg (light greenish-bluish grey to pale greenish-blue, hexagonal, film-coated) and 14 mg (pale blue to pastel blue, pentagonal, film-coated) tablets with dose strength imprinted on one side and engraved with corporate logo on other side.

FDA Approved Indication(s):

Aubagio is a de novo pyrimidine synthesis inhibitor/oral tablet indicated for:

- Treatment of patients with relapsing forms of multiple sclerosis.

Appendices

Appendix A: Abbreviation Key

FDA: Food and Drug Administration

MS: multiple sclerosis

Reviews, Revisions, and Approvals	Date	Approval Date
Policy split from CP.PHAR.18 MS Treatments. Criteria: added max dosing, clarified monotherapy restriction, removed re-authorization requirement for documented adherence, updated contraindications and reasons to discontinue, modified efficacy criteria to “Responding positively to therapy”. Modified renewal approval duration to 12 months. Requirement for the trial and failure of at least 2 preferred regimens from different classes added. Removed specific strength requirement from glatiramer.	06/16	08/16
Added age requirement. Removed MRI requirement. Removed hypersensitivity reaction and active infection contraindications. Removed reasons to discontinue.	07/17	08/17

References

1. Aubagio Prescribing Information. Cambridge, MA: Genzyme Corporation; November 2016. Available at <http://www.aubagio.com>. Accessed June 14, 2017.
2. Costello K, Halper J, Kalb R, Skutnik L, Rapp R. The use of disease-modifying therapies in multiple sclerosis, principles and current evidence – a consensus paper by the Multiple Sclerosis Coalition. July 2016. Accessed June 13, 2017.
3. Olek MJ. Disease-modifying treatment of relapsing-remitting multiple sclerosis. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2017. Available at www.UpToDate.com. Accessed June 13, 2017.
4. Olek MJ. Diagnosis of multiple sclerosis in adults. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2017. Available at www.UpToDate.com. Accessed June 13, 2017.

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

CLINICAL POLICY

Teriflunomide

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs and LCDs and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.